Nevro Corp (NVRO)

$9.185

-0.14

(-1.55%)▲

Live

Insights on Nevro Corp

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 116.17M → 101.89M (in $), with an average decrease of 12.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -8.98M → -25.40M (in $), with an average decrease of 182.9% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 45.7% return, outperforming this stock by 112.7%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 79.6% return, outperforming this stock by 173.3%

Performance

  • $9.08
    $9.37
    $9.19
    downward going graph

    1.2%

    Downside

    Day's Volatility :3.09%

    Upside

    1.92%

    downward going graph
  • $8.93
    $28.05
    $9.19
    downward going graph

    2.83%

    Downside

    52 Weeks Volatility :68.16%

    Upside

    67.24%

    downward going graph

Returns

PeriodNevro CorpSector (Health Care)Index (Russel 2000)
3 Months
-35.7%
-1.0%
0.0%
6 Months
-50.58%
9.6%
0.0%
1 Year
-66.1%
11.0%
0.0%
3 Years
-93.73%
18.5%
-22.6%

Highlights

Market Capitalization
343.4M
Book Value
$7.59
Earnings Per Share (EPS)
-2.28
PEG Ratio
-3.13
Wall Street Target Price
14.87
Profit Margin
-19.17%
Operating Margin TTM
-31.76%
Return On Assets TTM
-10.18%
Return On Equity TTM
-28.49%
Revenue TTM
430.7M
Revenue Per Share TTM
11.9
Quarterly Revenue Growth YOY
5.800000000000001%
Gross Profit TTM
276.4M
EBITDA
-87.0M
Diluted Eps TTM
-2.28
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.26
EPS Estimate Next Year
-2.11
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Hold
    4%Buy
    65%Hold
    30%Sell
Based on 23 Wall street analysts offering stock ratings for Nevro Corp(by analysts ranked 0 to 5 stars)
Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
2
Hold
15
15
14
Sell
7
7
7

Analyst Forecast

What analysts predicted

Upside of 61.89%

Current $9.19
Target $14.87

Company Financials

FY18Y/Y Change
Revenue
387.3M
↑ 18.56%
Net Income
-49.2M
↑ 34.23%
Net Profit Margin
-12.7%
↓ 1.48%
FY19Y/Y Change
Revenue
390.3M
↑ 0.77%
Net Income
-103.7M
↑ 110.72%
Net Profit Margin
-26.57%
↓ 13.87%
FY20Y/Y Change
Revenue
362.0M
↓ 7.23%
Net Income
-83.1M
↓ 19.89%
Net Profit Margin
-22.94%
↑ 3.63%
FY21Y/Y Change
Revenue
386.9M
↑ 6.87%
Net Income
-131.4M
↑ 58.14%
Net Profit Margin
-33.95%
↓ 11.01%
FY22Y/Y Change
Revenue
406.4M
↑ 5.03%
Net Income
3.0M
↓ 102.28%
Net Profit Margin
0.74%
↑ 34.69%
FY23Y/Y Change
Revenue
425.2M
↑ 4.63%
Net Income
-92.2M
↓ 3172.74%
Net Profit Margin
-21.69%
↓ 22.43%
Q4 FY22Q/Q Change
Revenue
113.8M
↑ 13.32%
Net Income
-19.2M
↓ 123.55%
Net Profit Margin
-16.86%
↓ 97.99%
Q1 FY23Q/Q Change
Revenue
96.3M
↓ 15.39%
Net Income
-35.0M
↑ 82.52%
Net Profit Margin
-36.36%
↓ 19.5%
Q2 FY23Q/Q Change
Revenue
108.8M
↑ 12.96%
Net Income
-24.7M
↓ 29.42%
Net Profit Margin
-22.72%
↑ 13.64%
Q3 FY23Q/Q Change
Revenue
103.9M
↓ 4.55%
Net Income
-23.5M
↓ 5.04%
Net Profit Margin
-22.61%
↑ 0.11%
Q4 FY23Q/Q Change
Revenue
116.2M
↑ 11.86%
Net Income
-9.0M
↓ 61.75%
Net Profit Margin
-7.73%
↑ 14.88%
Q1 FY24Q/Q Change
Revenue
101.9M
↓ 12.29%
Net Income
-25.4M
↑ 182.92%
Net Profit Margin
-24.94%
↓ 17.21%
FY18Y/Y Change
Total Assets
463.1M
↑ 2.0%
Total Liabilities
217.6M
↑ 6.22%
FY19Y/Y Change
Total Assets
469.6M
↑ 1.41%
Total Liabilities
253.3M
↑ 16.39%
FY20Y/Y Change
Total Assets
789.4M
↑ 68.09%
Total Liabilities
401.0M
↑ 58.3%
FY21Y/Y Change
Total Assets
574.5M
↓ 27.22%
Total Liabilities
270.9M
↓ 32.43%
FY22Y/Y Change
Total Assets
602.4M
↑ 4.85%
Total Liabilities
278.5M
↑ 2.81%
FY23Y/Y Change
Total Assets
635.7M
↑ 5.53%
Total Liabilities
330.3M
↑ 18.59%
Q4 FY22Q/Q Change
Total Assets
602.4M
↓ 0.51%
Total Liabilities
278.5M
↓ 0.73%
Q1 FY23Q/Q Change
Total Assets
574.4M
↓ 4.65%
Total Liabilities
273.2M
↓ 1.92%
Q2 FY23Q/Q Change
Total Assets
569.5M
↓ 0.85%
Total Liabilities
274.8M
↑ 0.58%
Q3 FY23Q/Q Change
Total Assets
561.6M
↓ 1.39%
Total Liabilities
275.9M
↑ 0.42%
Q4 FY23Q/Q Change
Total Assets
635.7M
↑ 13.2%
Total Liabilities
330.3M
↑ 19.71%
Q1 FY24Q/Q Change
Total Assets
596.1M
↓ 6.24%
Total Liabilities
317.5M
↓ 3.88%
FY18Y/Y Change
Operating Cash Flow
-5.7M
↓ 60.01%
Investing Cash Flow
6.4M
↑ 58.1%
Financing Cash Flow
7.8M
↓ 30.76%
FY19Y/Y Change
Operating Cash Flow
-50.2M
↑ 779.91%
Investing Cash Flow
32.3M
↑ 402.56%
Financing Cash Flow
32.1M
↑ 313.89%
FY20Y/Y Change
Operating Cash Flow
1.2M
↓ 102.37%
Investing Cash Flow
-369.9M
↓ 1244.04%
Financing Cash Flow
346.9M
↑ 980.94%
FY21Y/Y Change
Operating Cash Flow
-41.9M
↓ 3616.46%
Investing Cash Flow
201.7M
↓ 154.54%
Financing Cash Flow
-169.4M
↓ 148.83%
FY22Y/Y Change
Operating Cash Flow
24.7M
↓ 158.92%
Investing Cash Flow
64.3M
↓ 68.13%
Financing Cash Flow
-2.5M
↓ 98.55%
Q4 FY22Q/Q Change
Operating Cash Flow
-13.4M
↓ 116.92%
Investing Cash Flow
458.0K
↓ 100.81%
Financing Cash Flow
1.4M
↑ 3613.51%
Q1 FY23Q/Q Change
Operating Cash Flow
-29.3M
↑ 118.39%
Investing Cash Flow
-24.6M
↓ 5481.66%
Financing Cash Flow
-2.3M
↓ 265.43%
Q2 FY23Q/Q Change
Operating Cash Flow
-14.5M
↓ 50.53%
Investing Cash Flow
11.3M
↓ 145.74%
Financing Cash Flow
4.1M
↓ 281.35%
Q3 FY23Q/Q Change
Operating Cash Flow
-6.1M
↓ 58.01%
Investing Cash Flow
7.3M
↓ 35.4%
Financing Cash Flow
-1.0M
↓ 124.58%

Technicals Summary

Sell

Neutral

Buy

Nevro Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nevro Corp
Nevro Corp
-16.32%
-50.58%
-66.1%
-93.73%
-84.6%
Stryker Corporation
Stryker Corporation
4.27%
16.65%
22.1%
34.77%
82.03%
Boston Scientific Corp.
Boston Scientific Corp.
4.07%
37.85%
46.89%
79.63%
93.34%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.26%
27.0%
2.23%
-8.36%
51.45%
Abbott Laboratories
Abbott Laboratories
-2.62%
-2.21%
-0.86%
-5.87%
32.8%
Medtronic Plc
Medtronic Plc
0.44%
2.96%
-1.92%
-33.69%
-13.02%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nevro Corp
Nevro Corp
157.5
NA
-3.13
-2.26
-0.28
-0.1
NA
7.59
Stryker Corporation
Stryker Corporation
38.89
38.89
2.92
11.96
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.5
63.5
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.45
37.45
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
31.83
31.83
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
29.48
29.48
1.52
5.2
0.07
0.04
0.03
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nevro Corp
Nevro Corp
Hold
$343.4M
-84.6%
157.5
-19.17%
Stryker Corporation
Stryker Corporation
Buy
$129.9B
82.03%
38.89
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$111.1B
93.34%
63.5
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
51.45%
37.45
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$177.8B
32.8%
31.83
13.96%
Medtronic Plc
Medtronic Plc
Buy
$106.7B
-13.02%
29.48
11.36%

Institutional Holdings

  • Armistice Capital, LLC

    9.87%

  • BlackRock Inc

    9.19%

  • Vanguard Group Inc

    8.64%

  • ArrowMark Colorado Holdings, LLC (ArrowMark Partners)

    7.61%

  • Goldman Sachs Group Inc

    5.71%

  • Fred Alger Management, LLC

    5.67%

Company Information

headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.

Organization
Nevro Corp
Employees
1215
CEO
Mr. Roderick H. MacLeod
Industry
Health Technology

Discover More

FAQs